In addition to being a component of innate immunity and an ancient defense mechanism
against invading pathogens, complement activation also participates in the adaptive …

For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

In tumour immunology, complement has traditionally been considered as an adjunctive
component that enhances the cytolytic effects of antibody-based immunotherapies, such as …

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …

Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite its
undeniable therapeutic value, we still do not fully understand the mechanisms of action …

Cancer immunotherapy comprises a variety of treatment approaches, incorporating the
tremendous specificity of the adaptive immune system (T cells and antibodies) as well as the …

We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a
novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab …

Antibody‐dependent cellular cytotoxicity (ADCC) is a set of mechanisms that target cells
coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of …

The remarkable progress in engineering and clinical development of therapeutic antibodies
in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by …

Therapeutic monoclonal antibodies (mAbs) that target the CD20 antigen on B cells are
successfully used in the clinic for the depletion of B cells to treat various forms of cancer and …